Diet pills' potential questioned after Qsymia's miniscule sales

The very small sales of Vivus' prescription weight-loss drug Qsymia since it came to market last year highlights questions over the potential role that prescription drugs can play against obesity, Andrew Pollack writes. Aside from its unique problems, Qsymia also faces obstacles that other weight-loss treatments are likely to have, including safety issues, modest weight loss, lack of insurance reimbursement, plus a feeling among obese people and doctors that more willpower is the best weapon against excess weight, he writes. The drug is also affected by the problematic history of weight-loss treatments, their lack of coverage under Part D and the lack of resources, he writes.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief: